Inspire Medical Systems, Inc. — Q2 2020 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2020. Inspire develops and sells its FDA-approved neurostimulation system for moderate-to-severe obstructive sleep apnea, primarily to U.S. hospitals and ambulatory surgery centers, with sales in select European markets. Financial statements are unaudited.
Financial performance and position
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | $12.2 million | $18.0 million | $33.5 million | $34.3 million |
| Gross margin | 84.0% | 82.8% | 84.3% | 82.6% |
| Operating expenses | $33.0 million | $23.1 million | $67.5 million | $45.3 million |
| Operating loss | $(22.8) million | $(8.2) million | $(39.3) million | $(17.0) million |
| Net loss | $(23.1) million | $(7.7) million | $(39.3) million | $(15.9) million |
| Basic and diluted loss per share | $(0.88) | $(0.32) | $(1.56) | $(0.67) |
- Q2 revenue fell 32.4% year over year; first-half revenue fell 2.2%. U.S. first-half revenue increased 0.5%, while Europe declined 21.6%.
- Higher gross margins were attributed primarily to manufacturing efficiencies. Operating expenses rose substantially: first-half R&D increased 111.0% and SG&A 40.7%, reflecting product development, increased headcount, and marketing investment.
- Cash used in operating activities was $40.0 million in the first half, versus $23.8 million a year earlier. Capital expenditures were $0.6 million.
- At June 30, cash and cash equivalents were $211.2 million and investments were $31.3 million, totaling $242.6 million. Current assets were $267.1 million and current liabilities $13.0 million.
- Debt was $24.5 million outstanding, with no remaining availability under the facility. The stated minimum interest rate is 7.60%; interest-only payments run through April 2022, with maturity in March 2024. The company reported covenant compliance.
- On April 16, the company raised approximately $124.7 million net by issuing 2.3 million shares at $58 per share. Accumulated deficit was $219.5 million.
Changes, outlook, and risks
Management attributed the Q2 revenue decline to COVID-19 disruption: elective procedures and patient screenings were postponed from mid-March, with volumes recovering in May and June but remaining below pre-pandemic levels. Some Q2 procedures were rescheduled cases, and management said a backlog was building. A resurgence of infections and limited provider, hospital, and surgery-center capacity could further delay procedures and recovery.
The company expects the pandemic to continue adversely affecting revenue but provided no quantified revenue or earnings guidance. It said existing cash resources should fund operations and capital requirements for at least 12 months, despite expected reduced revenue. Management planned to continue R&D and capital investment, maintain planned Territory Manager expansion, and use virtual tools and telemedicine for patient education and physician training. No supply-chain disruption had been experienced to date; many suppliers are single source, and elevated inventory levels create obsolescence risk.
As of August 4, 2020, the company reported positive coverage policies from 56 U.S. commercial payors covering approximately 182 million lives; all seven Medicare Administrative Contractors had published final coverage policies in 2020. Japan reimbursement coverage was still being pursued. The company expects losses for several years and may need additional financing. Other disclosed risks include reimbursement and market adoption, competition, product quality and liability, supplier dependence, and COVID-related financial-market and operating disruption. No material legal proceedings were reported; no material changes to contractual obligations were reported.
Key facts for investors to verify
- Whether procedure volumes and the reported backlog recover, given renewed COVID-19 effects and capacity constraints.
- Whether revenue growth, especially in the U.S. and Europe, resumes while operating expenses and cash burn remain elevated.
- Whether the $242.6 million of cash and investments supports the stated 12-month funding outlook under prolonged disruption.
- Debt service and prepayment terms, including the variable-rate floor and balloon/final payment obligations.
- Progress in commercial-payor and Medicare reimbursement, international coverage, and expanded indications.